NCT05114148 - Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2025

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

DEVICE

Holmium-166 radioembolization

Individualized 166Ho-RE will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.

Trial Locations (1)

3584 CX

RECRUITING

UMC Utrecht, Utrecht